[{"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-001", "question": "A 58-year-old man with metastatic castration-resistant prostate cancer (mCRPC) on enzalutamide develops progressive disease with new liver metastases. He is switched to docetaxel plus prednisone. After 6 cycles, his PSA declines by 80% and liver lesions shrink, but he develops new-onset bilateral gynecomastia, mild hyperpigmentation of palmar creases, and worsening fatigue. Serum studies show: testosterone 12 ng/dL (low), LH 0.1 mIU/mL (low), FSH 0.2 mIU/mL (low), cortisol 4 mcg/dL (8 AM, low), ACTH 15 pg/mL (inappropriately normal), TSH 0.8 mIU/L, free T4 1.0 ng/dL. What is the most likely underlying mechanism for his new symptoms?", "options": ["Secondary adrenal insufficiency due to docetaxel-induced autoimmune hypophysitis", "Ectopic ACTH secretion from prostate cancer cells transforming to small cell neuroendocrine carcinoma", "Inhibition of CYP17A1 by residual enzalutamide leading to combined glucocorticoid and mineralocorticoid deficiency", "Docetaxel-induced primary testicular failure with subsequent feedback suppression of gonadotropins", "Paraneoplastic production of beta-hCG by treatment-emergent neuroendocrine-differentiated prostate cancer"], "answer": "C", "answer_index": 2, "explanation": "The clinical picture suggests combined glucocorticoid and androgen deficiency with low ACTH, consistent with secondary adrenal insufficiency due to central suppression. Enzalutamide is a potent androgen receptor inhibitor but also inhibits multiple CYP enzymes, including CYP17A1, which is required for glucocorticoid and androgen synthesis. When docetaxel suppresses tumor burden, residual enzalutamide (with a long half-life) continues to block adrenal steroidogenesis, causing a late-presenting adrenal crisis. Ectopic ACTH would elevate ACTH; autoimmune hypophysitis typically elevates TSH and causes other pituitary deficiencies; primary testicular failure elevates LH/FSH; beta-hCG causes gynecomastia but not adrenal insufficiency.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: N (No defensible answer). Verdict on keyed answer: Factually incorrect mechanism and pharmacokinetics. \\n\\nThe item contains multiple fatal flaws that make it unsolvable:\\n1. Pharmacology Error: The keyed answer (C) claims Enzalutamide inhibits CYP17A1. This is medically false; Enzalutamide is an androgen receptor antagonist. CYP17A1 inhibition is the mechanism of Abiraterone.\\n2. Pharmacokinetic Error: The patient has been on Docetaxel for 6 cycles (approx. 18 weeks). Enzalutamide (half-life ~6 days) would be fully washed out, making 'residual' inhibition impossible.\\n3. Clinical Contradiction: The stem describes hyperpigmentation (a sign of high ACTH/MSH seen in primary adrenal insufficiency) but reports low/normal ACTH (15 pg/mL). These findings are mutually exclusive.\\n4. Confounding: The patient is taking prednisone (standard with Docetaxel), which physiologically suppresses endogenous cortisol and ACTH. The low lab values are expected effects of current therapy.\\n\\nNo option is correct because the mechanism described in the key does not exist for the drug specified, and the clinical signs contradict the laboratory data.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: N (No defensible answer). Verdict on keyed answer: Factually incorrect mechanism and pharmacokinetics. \n\nThe item contains multiple fatal flaws that make it unsolvable:\n1. Pharmacology Error: The keyed answer (C) claims Enzalutamide inhibits CYP17A1. This is medically false; Enzalutamide is an androgen receptor antagonist. CYP17A1 inhibition is the mechanism of Abiraterone.\n2. Pharmacokinetic Error: The patient has been on Docetaxel for 6 cycles (approx. 18 weeks). Enzalutamide (half-life ~6 days) would be fully washed out, making 'residual' inhibition impossible.\n3. Clinical Contradiction: The stem describes hyperpigmentation (a sign of high ACTH/MSH seen in primary adrenal insufficiency) but reports low/normal ACTH (15 pg/mL). These findings are mutually exclusive.\n4. Confounding: The patient is taking prednisone (standard with Docetaxel), which physiologically suppresses endogenous cortisol and ACTH. The low lab values are expected effects of current therapy.\n\nNo option is correct because the mechanism described in the key does not exist for the drug specified, and the clinical signs contradict the laboratory data.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-002", "question": "A 32-year-old woman with common variable immunodeficiency (CVID) on monthly IVIG develops acute severe headache, photophobia, and neck stiffness 36 hours after her infusion. LP shows: opening pressure 28 cm H2O, WBC 2/μL, protein 40 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). Gram stain and culture negative. MRI brain with contrast is normal. She has had two similar but milder episodes in the past 12 months, always within 48 hours of IVIG. Which intervention is most likely to prevent recurrence while maintaining adequate immune protection?", "options": ["Switch to subcutaneous immunoglobulin (SCIG) at the same monthly dose", "Pre‑infusion high‑dose corticosteroid (e.g., methylprednisolone 1 g IV)", "Change IVIG product to a sucrose‑free, low‑osmolality formulation", "Administer IVIG at a slower infusion rate (e.g., over 72 hours) with pre‑hydration", "Replace IVIG with prophylactic antibiotics and as‑needed plasma infusions"], "answer": "A", "answer_index": 0, "explanation": "This describes aseptic meningitis secondary to IVIG, a well‑known complication related to high peak IgG levels and cytokine release. Switching to SCIG provides steady‑state IgG levels without peaks, dramatically reducing meningitis risk while maintaining protection. Slower infusion or changing formulation may reduce but not eliminate risk in susceptible patients. Pre‑infusion steroids are not routinely effective and pose long‑term risks. Discontinuing immunoglobulin replacement in CVID would lead to serious infections despite antibiotics.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Valid (V). Verdict: Keyed answer (A) is the correct best answer. The clinical vignette describes a patient with recurrent, severe CNS reactions (headache, meningismus) temporally associated with IVIG infusions. The key discriminating factor is the need to prevent recurrence of these severe peak-dose-dependent side effects. Switching to Subcutaneous Immunoglobulin (SCIG) maintains steady-state IgG levels, avoiding the high serum peaks that trigger aseptic meningitis or severe vascular headaches, making it the most effective preventive strategy. \\n\\nMedical Accuracy Issue: The explanation labels the condition 'aseptic meningitis,' but the vignette reports a CSF WBC of 2/μL. True drug-induced aseptic meningitis is characterized by CSF pleocytosis (often neutrophilic). The findings (high opening pressure, normal cells) are more consistent with IVIG-associated intracranial hypertension or severe migraine. However, the management for both conditions—when recurrent and severe—is switching to SCIG. Option A is phrased 'at the same monthly dose,' which implies the cumulative monthly exposure remains constant (though administered weekly), which is pharmacokinetically correct. Option D (72-hour infusion) is logistically impractical compared to SCIG. Minimal fix: Increase CSF WBC to >50/μL to match the 'aseptic meningitis' diagnosis or adjust the explanation.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Valid (V). Verdict: Keyed answer (A) is the correct best answer. The clinical vignette describes a patient with recurrent, severe CNS reactions (headache, meningismus) temporally associated with IVIG infusions. The key discriminating factor is the need to prevent recurrence of these severe peak-dose-dependent side effects. Switching to Subcutaneous Immunoglobulin (SCIG) maintains steady-state IgG levels, avoiding the high serum peaks that trigger aseptic meningitis or severe vascular headaches, making it the most effective preventive strategy. \n\nMedical Accuracy Issue: The explanation labels the condition 'aseptic meningitis,' but the vignette reports a CSF WBC of 2/μL. True drug-induced aseptic meningitis is characterized by CSF pleocytosis (often neutrophilic). The findings (high opening pressure, normal cells) are more consistent with IVIG-associated intracranial hypertension or severe migraine. However, the management for both conditions—when recurrent and severe—is switching to SCIG. Option A is phrased 'at the same monthly dose,' which implies the cumulative monthly exposure remains constant (though administered weekly), which is pharmacokinetically correct. Option D (72-hour infusion) is logistically impractical compared to SCIG. Minimal fix: Increase CSF WBC to >50/μL to match the 'aseptic meningitis' diagnosis or adjust the explanation.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-003", "question": "An 87‑year‑old man with moderate Alzheimer dementia (MoCA 14/30), hypertension, and chronic kidney disease (eGFR 28 mL/min/1.73m²) is admitted from assisted living for acute confusion and agitation. He has been on donepezil 10 mg daily for 3 years. In the ED, he receives lorazepam 1 mg IM for severe agitation, with minimal effect. Inpatient medications include amlodipine, losartan, and aspirin. Over 48 hours, he develops persistent non‑rhythmic myoclonic jerks of the face and limbs, fluctuating alertness, and autonomic instability (HR 110-140, BP 170/95). EEG shows generalized periodic discharges with triphasic morphology. MRI brain is unchanged from baseline (moderate atrophy). What is the most likely diagnosis?", "options": ["Creutzfeldt‑Jakob disease", "Serotonin syndrome from an undetected SSRI", "Donepezil toxicity in the setting of acute kidney injury", "Nonconvulsive status epilepticus due to underlying neurodegeneration", "Acute anticholinergic delirium from a newly started medication"], "answer": "C", "answer_index": 2, "explanation": "The presentation with myoclonus, autonomic instability, altered mental status, and triphasic waves on EEG in a patient on donepezil with advanced CKD suggests donepezil toxicity. Donepezil is renally excreted, and acute kidney injury (even mild) can precipitate toxicity. Triphasic waves are classically associated with metabolic/toxic encephalopathies, including acetylcholinesterase inhibitor toxicity. Creutzfeldt‑Jakob disease would show rapid progression and MRI diffusion abnormalities. Serotonin syndrome requires a serotonergic agent. Nonconvulsive status typically shows rhythmic epileptiform discharges. Anticholinergic delirium causes dry skin, not myoclonus or triphasic waves.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible)\\nVerdict on keyed answer: No defensible answer (Key relies on false medical premises)\\n\\nKey stem clues:\\n- 87M, CKD, on Donepezil.\\n- Acute agitation, myoclonus, autonomic instability (HR 110-140, BP 170/95).\\n- EEG: Generalized periodic discharges with triphasic morphology.\\n\\nMedical/Logical Issues:\\n1. Pharmacokinetics (Major Error): The rationale claims Donepezil toxicity is precipitated by AKI due to renal excretion. In reality, Donepezil is primarily metabolized by the liver (CYP450), and the FDA label explicitly states that renal impairment does not significantly affect clearance; no dose adjustment is needed for CKD.\\n2. Toxidrome Mismatch: Cholinergic toxicity (Donepezil) classically presents with bradycardia, hypotension, and secretions (DUMBELS). This patient has significant tachycardia and hypertension, which contradicts the diagnosis of cholinergic crisis. The presentation (myoclonus, autonomic instability, agitation) strongly resembles Serotonin Syndrome, but no serotonergic drug is listed in the stem.\\n3. EEG: While triphasic waves suggest metabolic/toxic encephalopathy, the specific drug implicated (Donepezil) does not fit the clinical signs or the pharmacokinetic mechanism described.\\n\\nConclusion: The item is medically inaccurate. Option C is based on false pharmacology and contradicts the vital signs. Option B fits the phenotype but lacks a drug source. No option is valid.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible)\nVerdict on keyed answer: No defensible answer (Key relies on false medical premises)\n\nKey stem clues:\n- 87M, CKD, on Donepezil.\n- Acute agitation, myoclonus, autonomic instability (HR 110-140, BP 170/95).\n- EEG: Generalized periodic discharges with triphasic morphology.\n\nMedical/Logical Issues:\n1. Pharmacokinetics (Major Error): The rationale claims Donepezil toxicity is precipitated by AKI due to renal excretion. In reality, Donepezil is primarily metabolized by the liver (CYP450), and the FDA label explicitly states that renal impairment does not significantly affect clearance; no dose adjustment is needed for CKD.\n2. Toxidrome Mismatch: Cholinergic toxicity (Donepezil) classically presents with bradycardia, hypotension, and secretions (DUMBELS). This patient has significant tachycardia and hypertension, which contradicts the diagnosis of cholinergic crisis. The presentation (myoclonus, autonomic instability, agitation) strongly resembles Serotonin Syndrome, but no serotonergic drug is listed in the stem.\n3. EEG: While triphasic waves suggest metabolic/toxic encephalopathy, the specific drug implicated (Donepezil) does not fit the clinical signs or the pharmacokinetic mechanism described.\n\nConclusion: The item is medically inaccurate. Option C is based on false pharmacology and contradicts the vital signs. Option B fits the phenotype but lacks a drug source. No option is valid.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-004", "question": "A 45‑year‑old woman with metastatic HER2‑positive breast cancer (bone, liver) on first‑line therapy with trastuzumab, pertuzumab, and docetaxel achieves a partial response after 6 cycles. Maintenance trastuzumab/pertuzumab is continued. One year later, surveillance CT shows a new 2 cm pancreatic tail mass, biopsy‑proven adenocarcinoma consistent with breast primary (ER‑/PR‑/HER2 3+ by IHC). Next‑generation sequencing of the pancreatic lesion reveals an activating mutation in PIK3CA (H1047R) and no HER2 amplification by NGS (though IHC remains 3+). She has never received a CDK4/6 inhibitor or everolimus. What is the most appropriate next systemic therapy?", "options": ["Continue trastuzumab/pertuzumab and add capecitabine", "Switch to trastuzumab deruxtecan (T‑DXd)", "Switch to lapatinib plus capecitabine", "Switch to everolimus plus exemestane", "Switch to alpelisib plus fulvestrant"], "answer": "B", "answer_index": 1, "explanation": "This represents HER2‑positive breast cancer with apparent HER2 discordance (IHC 3+ but no amplification by NGS) and acquired PIK3CA mutation. Trastuzumab deruxtecan (T‑DXd) is effective even in HER2‑low disease and has shown activity in HER2‑positive cancers resistant to trastuzumab/pertuzumab. Continuing dual HER2 blockade with chemotherapy is less likely to work given possible HER2‑negative clone emergence. Lapatinib/capecitabine is an older second‑line option but inferior to T‑DXd. Everolimus/exemestane or alpelisib/fulvestrant target hormone pathway/PIK3CA but are for HR‑positive disease; here the tumor is ER‑/PR‑.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The patient has HER2-positive (IHC 3+), hormone receptor-negative (HR-) metastatic breast cancer and has progressed on first-line trastuzumab/pertuzumab/taxane. Based on the DESTINY-Breast03 trial, the standard-of-care second-line therapy is trastuzumab deruxtecan (T-DXd), making Option B the unique best answer. The mention of a PIK3CA mutation is a distractor; alpelisib (Option E) is indicated only for HR-positive/HER2-negative disease. Similarly, everolimus (Option D) targets HR-positive disease. Lapatinib plus capecitabine (Option C) is an older, inferior option compared to T-DXd in this setting. The discordance between IHC 3+ and NGS (no amplification) does not preclude T-DXd use; IHC 3+ defines HER2-positivity for clinical decision-making, and T-DXd is active even in HER2-low states. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The patient has HER2-positive (IHC 3+), hormone receptor-negative (HR-) metastatic breast cancer and has progressed on first-line trastuzumab/pertuzumab/taxane. Based on the DESTINY-Breast03 trial, the standard-of-care second-line therapy is trastuzumab deruxtecan (T-DXd), making Option B the unique best answer. The mention of a PIK3CA mutation is a distractor; alpelisib (Option E) is indicated only for HR-positive/HER2-negative disease. Similarly, everolimus (Option D) targets HR-positive disease. Lapatinib plus capecitabine (Option C) is an older, inferior option compared to T-DXd in this setting. The discordance between IHC 3+ and NGS (no amplification) does not preclude T-DXd use; IHC 3+ defines HER2-positivity for clinical decision-making, and T-DXd is active even in HER2-low states. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-005", "question": "A 28‑year‑old woman with idiopathic anaphylaxis presents with recurrent episodes of urticaria, angioedema, wheezing, and hypotension occurring 2-3 times monthly despite high‑dose antihistamines and montelukast. She undergoes exhaustive evaluation: normal tryptase, negative specific IgE to foods/venoms/drugs, no mastocytosis on bone marrow biopsy, and no physical urticaria triggers. During a supervised oral challenge to placebo in clinic, she develops identical symptoms with hypotension. Serum collected during the event shows elevated prostaglandin D2 (PGD2) but normal histamine and tryptase. Which therapy is most likely to be effective in preventing future episodes?", "options": ["Omalizumab (anti‑IgE)", "Rituximab (anti‑CD20)", "Imatinib (tyrosine kinase inhibitor)", "Continuous intravenous epinephrine infusion", "NSAID (e.g., indomethacin) prior to suspected triggers"], "answer": "E", "answer_index": 4, "explanation": "Elevated PGD2 with normal histamine/tryptase during symptoms suggests a prostaglandin‑mediated disorder, possibly a mast cell activation syndrome variant or idiopathic flush‑related anaphylaxis. NSAIDs inhibit cyclooxygenase and reduce PGD2 production, which can prevent episodes in select patients with prostaglandin‑driven symptoms. Omalizumab targets IgE‑mediated pathways, not primarily prostaglandin‑mediated. Rituximab is for autoimmune conditions. Imatinib is for mastocytosis with KIT mutations. Continuous epinephrine is not a preventive therapy and carries high risk.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy / Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a patient with recurrent anaphylaxis characterized by isolated elevation of Prostaglandin D2 (PGD2) with normal histamine and tryptase, and no evidence of systemic mastocytosis or IgE-mediated allergy. This specific biochemical profile points to a prostaglandin-mediated disorder (a variant of mast cell activation syndrome or idiopathic anaphylaxis). The most logical mechanism-based therapy is to inhibit PGD2 production via cyclooxygenase inhibition, making an NSAID (Option E) the correct choice. While Omalizumab (Option A) is a standard therapy for idiopathic anaphylaxis, the specific lab finding of elevated PGD2 (and normal histamine) is a discriminator intended to prioritize NSAIDs over anti-IgE therapy. Imatinib is contraindicated as mastocytosis was ruled out. The phrase 'prior to suspected triggers' in Option E is slightly imprecise for an 'idiopathic' condition (which typically requires daily prophylaxis), but the mechanistic link between PGD2 and NSAIDs makes it the unique best answer among the choices. The 'reaction to placebo' with objective hypotension confirms the non-allergic, spontaneous nature of the attacks.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a patient with recurrent anaphylaxis characterized by isolated elevation of Prostaglandin D2 (PGD2) with normal histamine and tryptase, and no evidence of systemic mastocytosis or IgE-mediated allergy. This specific biochemical profile points to a prostaglandin-mediated disorder (a variant of mast cell activation syndrome or idiopathic anaphylaxis). The most logical mechanism-based therapy is to inhibit PGD2 production via cyclooxygenase inhibition, making an NSAID (Option E) the correct choice. While Omalizumab (Option A) is a standard therapy for idiopathic anaphylaxis, the specific lab finding of elevated PGD2 (and normal histamine) is a discriminator intended to prioritize NSAIDs over anti-IgE therapy. Imatinib is contraindicated as mastocytosis was ruled out. The phrase 'prior to suspected triggers' in Option E is slightly imprecise for an 'idiopathic' condition (which typically requires daily prophylaxis), but the mechanistic link between PGD2 and NSAIDs makes it the unique best answer among the choices. The 'reaction to placebo' with objective hypotension confirms the non-allergic, spontaneous nature of the attacks.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251216T183904770Z_deepseek-v3.2_seed131", "question_id": "20251216T183904770Z_deepseek-v3.2_seed131-006", "question": "An 82‑year‑old woman with aortic stenosis (mean gradient 38 mm Hg, AVA 0.9 cm²), COPD (FEV1 45%), and stage 3 CKD is admitted with syncope. She lives independently but reports declining energy over 6 months. She is evaluated by cardiology and deemed high risk for surgical AVR but a candidate for TAVR. During shared decision‑making, which factor, if present, would most strongly argue against proceeding with TAVR?", "options": ["Recent fall with subdural hematoma requiring reversal of apixaban 3 months ago", "Moderate‑severe mitral regurgitation due to annular dilation", "Life expectancy estimated at less than 12 months due to metastatic lung cancer diagnosed 2 months ago", "Frailty score consistent with slow gait and low grip strength but able to perform ADLs", "Asymptomatic 4 cm abdominal aortic aneurysm noted on pre‑TAVR CT"], "answer": "C", "answer_index": 2, "explanation": "TAVR is indicated to improve quality of life and survival in patients with severe symptomatic aortic stenosis whose life expectancy is >12 months. A life expectancy <12 months due to metastatic cancer makes the procedural risks and recovery burdens unjustifiable. Recent subdural hematoma is a relative contraindication but may be timed. Moderate‑severe MR often improves post‑TAVR. Frailty alone does not preclude TAVR if the patient can participate in rehabilitation. A 4 cm AAA is below threshold for repair and not a contraindication.", "generator_model": "deepseek-v3.2", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Geriatrics", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best\\n\\nThe item presents a standard clinical decision-making scenario regarding contraindications for Transcatheter Aortic Valve Replacement (TAVR). The stem describes a high-risk patient with symptomatic severe aortic stenosis. The question asks for the factor most strongly arguing against the procedure.\\n\\nKeyed option C (life expectancy < 12 months due to metastatic cancer) is the correct best answer. Current ACC/AHA guidelines for valvular heart disease explicitly state that intervention is indicated only if the patient's expected survival is greater than 1 year with a reasonable quality of life. Performing TAVR in a patient with metastatic cancer and limited life expectancy is considered futile.\\n\\nOption A (recent SDH) presents a bleeding risk for post-TAVR antithrombotic therapy but is a relative contraindication that can often be managed (e.g., timing, LAA closure). Option B (MR) and D (frailty) are risk factors but not absolute contraindications; TAVR is often the preferred modality for frail patients. Option E (4 cm AAA) is an incidental finding below the repair threshold.\\n\\nThe item is logically sound, medically accurate, and relies on widely accepted guideline criteria for futility.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best\n\nThe item presents a standard clinical decision-making scenario regarding contraindications for Transcatheter Aortic Valve Replacement (TAVR). The stem describes a high-risk patient with symptomatic severe aortic stenosis. The question asks for the factor most strongly arguing against the procedure.\n\nKeyed option C (life expectancy < 12 months due to metastatic cancer) is the correct best answer. Current ACC/AHA guidelines for valvular heart disease explicitly state that intervention is indicated only if the patient's expected survival is greater than 1 year with a reasonable quality of life. Performing TAVR in a patient with metastatic cancer and limited life expectancy is considered futile.\n\nOption A (recent SDH) presents a bleeding risk for post-TAVR antithrombotic therapy but is a relative contraindication that can often be managed (e.g., timing, LAA closure). Option B (MR) and D (frailty) are risk factors but not absolute contraindications; TAVR is often the preferred modality for frail patients. Option E (4 cm AAA) is an incidental finding below the repair threshold.\n\nThe item is logically sound, medically accurate, and relies on widely accepted guideline criteria for futility.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]